Table 1 Summary of registered randomized trials on the role of therapeutic plasma exchange or insulin therapy in the setting of hypertriglyceridemic acute pancreatitis from the clinical trials registry
Trial No, acronym | study design, main country | N of patients (planned) | inclusion criteria | treatment arms | status of the study |
|---|---|---|---|---|---|
NCT03342807, Bi-TPAI trial [72] | multicentric RCT, China | 220 | HTG-AP | 1) intensive insulin (0.1–0.3 IU/kg/h) ± glucose 2) daily TPE | planned 2017–2020, protocol published, status unclear |
NCT03501680 | RCT, China | 200 | moderate / severe HTG-AP | 1) intensive insulin (glucose 4.5-6 mmol/l) 2) standard insulin (glucose 8–10 mmol/l) 3) TPE | planned 2018–2020 |
ChiCTR1800020415 | multicentric RCT, China | 190 | severe HTG-AP | 1) TPE 2) conservative | planned 2019–2021, recruiting |
ChiCTR2000037754 | single-center RCT, China | 60 | HTG-AP | 1) DFPP 2) conservative | planned 2020–2022 |
ChiCTR1900022028 | multicentric RCT, China | 178 | HTG-AP | 1) TPE 2) CRRT | planned 2019–2022 |
ChiCTR2100049081 | single-center RCT, China | 180 | HTG-AP + SIRS | 1) TPE 2) conservative | planned 2021–2023 |
NCT05487833 | single-center RCT, Slovenia | 30 | HTG-AP | 1) low dose insulin (4 IU / 500 ml 5% glucose in normal saline) 2) conservative | planned 2022–2024 |
ISRCTN41530928, ELEFANT trial [64] | multicentric, Hungary | 495 | HTG-AP | 1) TPE 2) intensive insulin (0.1 IU/kg/h) + 5% glucose + enoxaparin 4000 IU / 12 h s.c. 3) fluids only | planned 2020–2024 |